Cancer Biologics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, China - Size and Forecast 2024-2028

Cancer Biologics Market 2024-2028

The global cancer biologics market size is estimated to grow by USD 51.08 billion, at a CAGR of 9.18% between 2023 and 2028. 

The growth of the market is significantly propelled by the emphasis on personalized medicines, marking a departure from the traditional one-size-fits-all model. Personalized medicine, tailored to the unique genetic and molecular characteristics of individual cancer patients, offers more targeted and effective therapies, particularly in the context of the heterogeneous nature of cancer. Cancer biologics, designed to interact with specific molecular targets, seamlessly align with the personalized medicine paradigm. Further, advancements in genomics and molecular profiling technologies contribute to a deeper understanding of the molecular intricacies of various cancers, facilitating the development that precisely intervenes in the pathways driving a particular patient's cancer. The growing recognition of inherent genetic diversity among patients fuels the demand for personalized treatments, driving the significant growth of the market during the forecast period.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by Product, Route Of Administration and Geography Analysis

Product Analysis 

Monoclonal antibodies

The market share growth by the monoclonal antibodies segment will be significant during the forecast period. Monoclonal antibodies are an important part of targeted therapy or immunotherapy for the treatment. The monoclonal antibodies block tumor growth by acting on specific targets and preventing cancer progression or carcinogenesis. These targets are the cascade proteins that are responsible for angiogenesis. The monoclonal antibodies alter the way a cancer cell divides, repairs, grows, and interacts with other cells.

Get a glance at the market contribution of various segments Download PDF Sample

The monoclonal antibodies segment was the largest and was valued at USD 51.65 billion in 2018. Some of the approved monoclonal antibodies available on the market include Herceptin, Avastin, MabThera/Rituxan, XGEVA, Vectibix, BLINCYTO, OPDIVO, EMPLICITI, YERVOY, LARTRUVO, PORTRAZZA, ERBITUX, CYRAMZA, PERJETA, KADCYLA, TECENTRIQ, GAZYVA, and KEYTRUDA. The growth momentum of the monoclonal antibodies segment is accelerating due to the new drug approvals as well as the presence of a large number of monoclonal antibodies in the pipeline for the treatment. The pipeline for biologics is dominated by monoclonal antibodies. Therefore, the presence of these monoclonal antibodies in the market are expected to contribute to the growth of the monoclonal antibodies segment of the market during the forecast period.

Route Of Administration Analysis 

Injectable

The injectable route of administration is a common and well-established method for delivering cancer biologics. This approach involves introducing therapeutic agents directly into the bloodstream through various injection methods, such as intravenous (IV), subcutaneous (SC), or intramuscular (IM) injections. Injectable cancer biology often consists of large, complex molecules that necessitate precise delivery to ensure effective treatment. Several injectable cancer biologics have been developed for the treatment of various cancers. However, one challenge with injectable cancer biologics lies in the potential development of injection site reactions, which can include redness, swelling, or discomfort. These reactions are closely monitored during clinical trials and real-world use to ensure patient safety and optimize treatment outcomes. These factors are expected to contribute to the growth of the injectable segment of the market during the forecast period.

Oral

The oral route of administration for cancer biologics has emerged as a promising alternative to traditional methods such as intravenous injections. This approach involves delivering therapeutic agents in the form of oral medications, typically in the form of tablets or capsules. The appeal of oral administration lies in its convenience and potential to enhance patient compliance, as it eliminates the need for frequent hospital visits for intravenous treatments. Further, the potential benefits extend beyond patient convenience. This mode of administration may offer a more patient-friendly experience, reducing the burden of treatment on individuals battling cancer. Additionally, oral delivery could contribute to healthcare cost reduction by minimizing the need for specialized medical facilities and personnel required for intravenous administration. These factors are expected to contribute to the growth of the oral segment of the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The rising incidence of cancer in countries such as the US and Canada is driving the market in North America. The incidence of cancers such as breast cancer, esophageal cancer, pancreatic cancer, and gynecological cancers, along with rare cancers such as neuroblastoma, is continuously increasing. As per the CDC, about 237,000 cases of breast cancer are diagnosed in women and about 2,100 in men each year in the US. As per the NIH, it was estimated that about 650 children are diagnosed each year with neuroblastoma in the US. In addition to the rising incidence of cancer, the accelerated approvals granted by regulatory authorities such as the FDA are propelling the market growth.

Additionally, biologics such as monoclonal antibodies are covered under reimbursement schemes in the US. For example, UNITUXIN, an immunotherapy drug for the treatment of neuroblastoma is covered under Medicare Part B. The huge prevalence of cancer and the availability of favorable reimbursement schemes are the factors contributing to the growth of the market in the US. Moreover, organizations such as the American Cancer Society, the American Breast Cancer Foundation (ABCF), and the Esophageal Cancer Awareness Association (ECAA) are taking initiatives to support patients, caregivers, survivors, family members, and anyone at risk of the disease. This, in turn, is driving the market in the region during the forecast period. 

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Amgen Inc. - The company offers cancer biologics under the brand name Lumakras. This is offered for patients with KRAS G12C mutated advanced colorectal cancer CRC.

• AstraZeneca Plc
• Bayer AG
• Biocon Ltd.
• Biogen Inc.
• Bristol Myers Squibb Co.
• Celltrion Co. Ltd
• Cipla Ltd.
• Dr Reddys Laboratories Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline Plc
• Jazz Pharmaceuticals Plc.
• Johnson and Johnson
• Lupin Ltd.
• Merck KGaA
• Novartis AG
• Ono Pharmaceutical Co. Ltd.
• Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key market growth analysis through drivers, trends, and challenges. 

Key Drivers

The rising global incidence of cancer is notably driving market growth. Cancer is one of the most common chronic diseases and is becoming a major health issue as it is increasing the mortality rate globally. Major factors that lead to cancer include genetic mutations, environmental factors such as tobacco smoking and pollution, and changing dietary patterns. The rising prevalence of these factors has directly contributed to the increased global incidence of cancer. As a result, cancer has become the second leading cause of death worldwide. In 2020, there were 19.3 million new cancer cases and 10 million cancer-related deaths worldwide.

Moreover, healthcare providers need data related to cancer incidences to make decisions regarding the volume of equipment and medicines to be purchased for treatment and to develop awareness and prevention programs. Therefore, the rising incidence and prevalence of cancer among the population are expected to increase the demand for cancer biologics. Thus, the rapidly rising incidence throughout the world is a major factor that will drive the growth of the market during the forecast period.

Significant  Trends

The untapped potential of cancer biologics in developing countries is an emerging trend shaping market growth. Cancer is a deadly epidemic disease across the globe; however, the condition is turning out to be a major killer in developing countries. Cancers are more common in developing countries. Countries such as India, China, and Brazil are garnering the attention of many global pharmaceutical companies dealing with oncology drugs. Many factors, such as the large global population and the rising geriatric population, are driving the growth of the healthcare sector significantly in developing countries.

In addition, developing countries, especially South Asian countries such as India and China, are heavily dependent on chemotherapy drugs for cancer treatment. As chemotherapy drugs have many side effects, consumer preference is expected to increase in Asia and other developing regions. These factors will drive the market growth and trends during the forecast period.

Major  Challenges

Patent expiry of major cancer biologics is a significant challenge hindering market growth. The expiry of the patent for a particular drug paves the way for the emergence of its low-priced generic versions in the market. In the case of biologics, the low-priced generic versions are referred to as biosimilars. A biosimilar (also known as a follow-on biologic or subsequent entry biologic) is an identical version of the bio-originator product and has similar pharmacokinetic and pharmacological properties.

Moreover, the biosimilar versions of most of the cancer biologics, which have faced patent expiration, have already entered the market. Hence, the emergence of biosimilars due to patent expiration of biologics is expected to hinder the growth of the market during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market forecasting report includes the adoption lifecycle of the market research and growth, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market analysis and report also include key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.

 Customer Landscape

Market Analyst Overview

The global cancer biologics market is witnessing exponential growth, driven by the increasing demand for innovative treatments and advancements in biotechnology. Biologic drugs sourced from living organisms such as animals, humans, and microorganisms offer targeted therapies, including monoclonal antibodies, vaccines, cells, allergens, tissues, genes, and recombinant proteins. Regulatory bodies like the FDA play a crucial role, with 47 biologics receiving novel indications, particularly in oncology, with 20 approvals in 2019 alone.

Clinical trials exploring diverse modalities like adoptive cell transfer, gene therapy, and immunotherapy are reshaping treatment paradigms. Targeted approaches such as angiogenesis inhibitors and chimeric antigen receptor (CAR) T-cell therapy are gaining prominence. Companies like Ologics and CUSABIO are driving innovation in this competitive landscape.

Segment-wise, monoclonal antibodies, growth factors, blood products, vaccines, and toxoids dominate the market. Techniques like immunohistochemistry and next-generation sequencing are facilitating personalized medicine approaches. Medications like Herceptin, Avastin, Rituxan, and Remicade are pivotal in cancer management. Collaborations with organizations like the FDA and EMA ensure stringent regulatory compliance and quality assurance. With advancements in genomics and targeted drug therapy, the market continues to evolve, offering hope for improved patient outcomes.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Product Outlook
  • Monoclonal antibodies
  • Cell and gene therapy
  • Vaccines
  • Others

• Route Of Administration Outlook
  • Injectable
  • Oral

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina 
    • Australia 

Cancer Biologics Market Scope
Report Coverage	Details
Page number	169
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 9.18%
Market Growth 2024-2028	USD 51.08 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	8.16
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 47%
Key countries	US, Canada, UK, Germany, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Amgen Inc., AstraZeneca Plc, Bayer AG, Biocon Ltd., Biogen Inc., Bristol Myers Squibb Co., Celltrion Co. Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., and Viatris Inc.
Market dynamics	Parent market trends and analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the market between 2024 and 2028
• Precise estimation of the size and its contribution to the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch